Metcalfe David A's Form 4 filing
Nextgen Healthcare, Inc. (NXGN) · filed Apr 26, 2022
- Accession no.
- 0001209191-22-025636
- Filed
- Apr 26, 2022
- Trade date
- Apr 25, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $680.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metcalfe David ACIK 0001664295 | Officer (Chief Technology Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 25, 2022 | Common Stock | MOption exerciseAcquired | +33,838 | $14.20 | +$480,499.6 | 188,851 | Direct | |
| Apr 25, 2022 | Common Stock | SSaleDisposed | −33,838 | $20.11F2 | −$680,482.18 | 155,013 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 25, 2022 | Common Stock | MOption exerciseDisposed | −33,838 | $0.00 | $0 | 166,162 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.22. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request.
Referenced by the price of 1 transaction in Table I.